The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

Condition(s) studied

Study summary

Bronchiectasis is a heterogeneous airway disease with diverse causes, making precise diagnosis, prognosis, and treatment response prediction challenging. Identifying patient subgroups (phenotypes) and molecular profiles (endotypes) can enhance individualized assessment and management. While prior studies, primarily in European populations, have identified key phenotypes and endotypes, their relevance to Chinese patients remains unclear due to geographic and clinical differences. Specific causes of bronchiectasis, such as allergic bronchopulmonary aspergillosis (ABPA) and primary ciliary dyskinesia (PCD), may also exhibit distinct pathophysiology requiring further exploration. The C-BRIDGE Study seeks to characterize phenotypes and endotypes in Chinese bronchiectasis patients during stable disease and exacerbations, evaluate differences in clinical outcomes across these subgroups, and develop personalized medicine strategies based on these findings, applicable in China and globally.

Primary Objective: To identify molecular endotypes of bronchiectasis that accurately predict prognosis and guide treatment responses.

Secondary Objectives:

To characterize molecular endotypes of stable bronchiectasis in Chinese patients.

To define molecular endotypes of bronchiectasis exacerbations in Chinese patients.

To investigate molecular endotypes specific to allergic bronchopulmonary aspergillosis (ABPA).

To explore genotypes and inflammatory endotypes of cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) in Chinese patients.

To validate candidate biomarkers for stable and exacerbation endotypes to support stratified medicine.

To conduct in vivo or in vitro proof-of-concept studies using phenotypic data to identify patient subgroups likely to benefit from specific pharmacological interventions.

Study Design: This observational cohort study will link identified patient subgroups with meaningful clinical outcomes to inform prognosis and optimize treatment strategies.

Eligibility

Primary outcome measure(s)

• Frequency of bronchiectasis exacerbations — 2 years
  Worsening of respiratory symptoms, as defined by the EMBARC/BRR criteria (Eur Respir J. 2017;49(6):1700051), requiring adjustments to treatment strategies.

Trial sites (9)

More Shanghai Pulmonary Hospital, Shanghai, China trials in China

Other trials for the same condition